Liver NF-κB and AP-1 DNA binding in obese patients

Obesity

Volumn 17, Issue 5, 2009, Pages 973-979

  Videla, Luis A ^a   Tapia, Gladys ^a   Rodrigo, Ramón ^a   Pettinelli, Paulina ^a   Haim, Daniela ^a   Santibãez, Catherine ^a   Araya, A Verónica ^b   Smok, Gladys ^b   Csendes, Attila ^b   Gutierrez, Luis ^b   Rojas, Jorge ^b   Castillo, Jaime ^b   Korn, Owen ^b   Maluenda, Fernando ^b   Díaz, Juan C ^b   Rencoret, Guillermo ^b   Poniachik, Jaime ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPID; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1;

ADULT; ARTICLE; BLOOD; BODY MASS; CHOLECYSTECTOMY; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER; LIVER FUNCTION TEST; MALE; METABOLISM; MORBID OBESITY; OBESITY; OXIDATIVE STRESS; PATHOLOGY; STOMACH BYPASS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLECYSTECTOMY; FATTY LIVER; FEMALE; GASTRIC BYPASS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; LIVER FUNCTION TESTS; MALE; NF-KAPPA B; OBESITY; OBESITY, MORBID; OXIDATIVE STRESS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP-1;

EID: 67349085771     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.601     Document Type: Article

References (38)

1. Angulo P. Nonalcololic fatty liver disease. N Eng J Med 2002;346: 1221-1231.
2. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Rad Biol Med 2004;37:1499-1507.
3. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12:555-558.
4. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-1588.
5. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non alcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
6. Araya J, Rodrigo R, Videla LA et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004;106:635-643.
7. Aronis A, Madar Z, Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radio Biol Med 2005;38:1221 -1230.
8. Videla LA, Rodrigo R, Orellana M et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004;106: 261-268.
9. Malaguarnera L, Di Rosa M, Zambito AM et al. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 2006;55:1313-1320.
10. Elizondo A, Araya J, Rodrigo R et al. Polyunsaturated fatty acids pattern in liver and erythrocyte phospholipids from obese patients. Obesity 2007;15:24-31.
11. Seki S, Kitada T, Yamada T et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
12. Garcia-Monzón C, Martín-Pérez E, lacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-724.
13. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.
14. Schwabe RR Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130:1886-1900.
15. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measured of antioxidant power: the FRAP assay. Anal Biochem 1996;239:70-76.
16. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
17. Deryckere F Gannon F A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues. Biotechniques 1994;16:405.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
19. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from Polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
20. Tran-Thi TA, Decker K, Baeuerle PA. Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. Hepatology 1995;22:613-619.
21. Ribeiro PS, Cortez-Pinto H, Sola S et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99: 1708-1717.
22. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006;72:1493-1505.
23. Kamata H, Honda S, Maeda S et al. Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-661.
24. Hayden MS, Ghosh D. Signaling to NF-kappaB. Genes Dev 2004;18: 2195-2224.
25. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944-948.
26. Shi H, Kokoeva MV, Inouye K et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025.
27. Evans JL, Maddux BA, Goldfine ID. The molecular basis of oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005;7:1040-1052.
28. Wigg AJ, Roberts-Thomson IC, Dymock RB et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211.
29. Fu XS, Jiang F Cisapride decreasing orocecal transit time in patients with nonalcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 2006;5:534-537.
30. Ruiz AG, Casafont F, Crespo J et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17:1374-1380.
31. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004;172:2522-2529.
32. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-419.
33. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
34. Pérez-Carreras M, Del Hoyo P, Martin MA et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
35. Crespo J, Cayón A, Fernández-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 ;34:1158-1563.
36. Strimpakos AS, Shrama RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008;10:511-545.
37. Leclercq IA, Farrell GC, Sempoux C, dela Peña A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004;41:926-934.
38. Reyes-Gordillo K, Segovia J, Shibayama M et al. Curcumin protects against acute liver damage on the rat by inhibiting NF-kappaB proinflammatory cytokines production and antioxidant stress. Biochim Biophys Acta 2007;1770;989-996.